BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that it has commenced an investigation on behalf of MabVax Therapeutics Holdings, Inc. (“MabVax” or the “Company”) (Nasdaq: MBVX) investors concerning the Company and its officers’ possible violations of federal securities laws.
On May 24, 2018, MabVax received notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires the timely filing of periodic reports with the U.S. Securities and Exchange Commission. The notice was sent as a result of the delay in the filing of the Company's Quarterly Report on Form 10-Q for the period ending March 31, 2018 (the "Form 10-Q"). On this news, shares of MabVax fell significantly, thereby injuring investors.
If you purchased MabVax securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to firstname.lastname@example.org, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.